Real-world use and 6-month effectiveness of vedolizumab subcutaneous in IBD patients: results of the VEDO-IBD study

被引：0
|
作者：
Plachta-Danielzik, S. [1 ]
Bokemeyer, B. [1 ,2 ,3 ]
Efken, P. [4 ]
Mohl, W. [5 ]
Hoffstadt, M. [6 ]
Krause, T. [7 ]
Schweitzer, A. [8 ]
Schnoy, E. [9 ]
Ehehalt, R. [10 ]
Trentmann, L. [11 ]
Teich, N. [12 ]
Atreya, R. [13 ]
Franzenburg, S. [1 ]
Hartmann, P.
Wenske, T. [1 ]
Schreiber, S. [1 ]
机构：
[1] Competence Network IBD, Study Dept, Kiel, Germany
[2] Interdisciplinary Crohn Colitis Ctr Minden, Crohn Colitis Ctr, Minden, Germany
[3] Univ Hosp Schleswig Holstein Campus Kiel, Clin Gen Internal Med 1, Kiel, Germany
[4] Gastroenterol Practice Minden, Minden, Germany
[5] Ctr Gastroenterol Saar MVZ, Saarbrucken, Germany
[6] Gastroenterol Practice Iserlohn, Iserlohn, Germany
[7] Gastroenterol Practice Kassel, Kassel, Germany
[8] Gastroenterol Practice Muenster, Munster, Germany
[9] Univ Hosp Augsburg, III Med Clin, Augsburg, Germany
[10] Gastroenterol Practice Heidelberg, Heidelberg, Germany
[11] Gastroenterol Practice Bremen, Bremen, Germany
[12] Gastroenterol Practice Leipzig, Leipzig, Germany
[13] Friedrich Alexander Univ Erlangen Nuernberg, Med Clin 1, Erlangen, Germany
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P784
引用
收藏
页码：918 / 919
页数：2
相关论文
共 50 条
  • [1] Predictors of Response to Vedolizumab in Patients with Ulcerative Colitis: Results from the Greek VEDO-IBD Cohort
    Bamias, Giorgos
    Kokkotis, Georgios
    Gizis, Michalis
    Kapizioni, Christina
    Karmiris, Konstantinos
    Koureta, Evgenia
    Kyriakos, Nikolaos
    Leonidakis, Georgios
    Makris, Konstantinos
    Markopoulos, Panagiotis
    Michalopoulos, Georgios
    Michopoulos, Spyridon
    Papaconstantinou, Ioannis
    Polymeros, Dimitrios
    Siakavellas, Spyros, I
    Triantafyllou, Konstantinos
    Tsironi, Eftychia
    Tsoukali, Emmanouela
    Tzouvala, Maria
    Viazis, Nikos
    Xourafas, Vassileios
    Zacharopoulou, Eirini
    Zampeli, Evanthia
    Zografos, Konstantinos
    Papatheodoridis, George
    Mantzaris, Gerasimos
    DIGESTIVE DISEASES AND SCIENCES, 2022, 67 (03) : 1007 - 1017
  • [2] Predictors of Response to Vedolizumab in Patients with Ulcerative Colitis: Results from the Greek VEDO-IBD Cohort
    Giorgos Bamias
    Georgios Kokkotis
    Michalis Gizis
    Christina Kapizioni
    Konstantinos Karmiris
    Evgenia Koureta
    Nikolaos Kyriakos
    Georgios Leonidakis
    Konstantinos Makris
    Panagiotis Markopoulos
    Georgios Michalopoulos
    Spyridon Michopoulos
    Ioannis Papaconstantinou
    Dimitrios Polymeros
    Spyros I. Siakavellas
    Konstantinos Triantafyllou
    Eftychia Tsironi
    Emmanouela Tsoukali
    Maria Tzouvala
    Nikos Viazis
    Vassileios Xourafas
    Eirini Zacharopoulou
    Evanthia Zampeli
    Konstantinos Zografos
    George Papatheodoridis
    Gerasimos Mantzaris
    Digestive Diseases and Sciences, 2022, 67 : 1007 - 1017
  • [3] REAL-WORLD EXPERIENCE OF SUBCUTANEOUS VEDOLIZUMAB FOR TREATMENT OF IBD IN NHS TAYSIDE
    McLean, Mairi
    Cartlidge, Peter
    Fyall, Julie
    Paterson, Jacqueline
    Mowat, Craig
    Groome, Max
    McLean, Mairi H.
    GUT, 2022, 71 : A58 - A59
  • [4] Real-world experiences of switching to subcutaneous formulation in IBD patients on maintenance vedolizumab treatment
    Bacsur, P.
    Resal, T.
    Farkas, B.
    Sarlos, P.
    Ilias, A.
    Kata, D.
    Balint, A.
    Fabian, A.
    Bor, R.
    Szepes, Z.
    Molnar, T.
    Farkas, K.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1269 - I1270
  • [5] Vedolizumab Dose Escalation in a Real-World Cohort of IBD Patients
    Zelinkova, Z.
    Kadleckova, B.
    Lucenicova, J.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S454 - S454
  • [6] Comparative real-world effectiveness and persistence of vedolizumab versus anti-TNF therapy in biologic-naive patients with Crohn's disease with propensity score adjustment: two-year maintenance phase results from the prospective VEDO-IBD study
    Bokemeyer, B.
    Plachta-Danielzik, S.
    Efken, P.
    Mohl, W.
    Hoffstadt, M.
    Krause, T.
    Schweitzer, A.
    Schnoy, E.
    Atreya, R.
    Teich, N.
    Trentmann, L.
    Ehehalt, R.
    Franzenburg, S.
    Hartmann, P.
    di Giuseppe, R.
    Schreiber, S.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 543 - 543
  • [7] P0744 Observational Real-World Study of Switching from Intravenous to Subcutaneous Vedolizumab in IBD Patients: Clinical and Pharmacokinetic Analysis
    Palomares, M. T. Diz Lois
    de-Acosta, M. Barreiro
    Lopez, A. Baz
    Sanchez, A. Porta
    Pazos, L. Elberdin
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1441 - i1442
  • [8] REAL-WORLD OUTCOMES AFTER VEDOLIZUMAB DISCONTINUATION IN A TERTIARY IBD COHORT
    Sebepos-Rogers, Gregory
    Fragkos, Konstantinos
    Saravanapavan, Hajeena
    Barragry, John
    Koo, Hui Fen
    Ko, Ho Juen
    Parisi, Ioanna
    Seward, Edward
    McCartney, Sara
    Bloom, Stuart
    Mehta, Shameer
    Rahman, Farooq
    GUT, 2021, 70 : A81 - A82
  • [9] Effectiveness and safety of vedolizumab in IBD patients: a multicentre experience of "real world data" from the UK
    Lenti, M. V.
    Levison, S.
    Eliadou, E.
    Willert, R.
    Kemp, K.
    Stansfield, C.
    Assadsangabi, A.
    Singh, S.
    Crooks, B.
    Tattersall, S.
    Kenneth, C.
    Subramanian, S.
    Probert, C.
    Smith, P.
    Liu, E.
    Limdi, J. K.
    Hamlin, P. J.
    Selinger, C. P.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S347 - S347
  • [10] Prevalence and real-world management of vedolizumab-associated enthesitis in successfully treated IBD patients
    Di Ruscio, Mirko
    Tinazzi, Ilaria
    Variola, Angela
    Geccherlel, Andrea
    Marchetta, Antonio
    McGonagle, Dennis
    RHEUMATOLOGY, 2021, 60 (12) : 5809 - 5813
12345